Aspen Aerogels (ASPN)
(Delayed Data from NYSE)
$16.64 USD
+0.01 (0.06%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $16.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.64 USD
+0.01 (0.06%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $16.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Zacks News
Aspen Aerogels (ASPN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of 91.67% and 0.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Aspen Aerogels (ASPN) This Earnings Season?
by Zacks Equity Research
Aspen Aerogels (ASPN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Owens Corning (OC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Owens Corning (OC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aspen Aerogels (ASPN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Aspen Aerogels (ASPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aspen (ASPN) Provides Preliminary Revenue Results & Guidance
by Zacks Equity Research
Aspen (ASPN) expects a positive adjusted EBITDA for the fourth quarter on strong revenues and operating efficiencies.
Zacks.com featured highlights include Aspen Aerogels, AxoGen and Credo Technology Group
by Zacks Equity Research
Aspen Aerogels, AxoGen and Credo Technology Group are part of the Zacks Screen of the Week article.
3 Stocks Worth a Look for Solid Earnings Acceleration
by Tirthankar Chakraborty
Keep a tab on stocks such as Aspen Aerogels (ASPN), AxoGen (AXGN) and Credo Technology Group (CRDO) for superb earnings acceleration.
Take the Zacks Approach to Beat the Market: Boeing, McDonald's, Monster Beverage in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Aspen Aerogels (ASPN) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Aspen Aerogels (ASPN) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Wall Street Analysts Think Aspen Aerogels (ASPN) Could Surge 54.53%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Aspen Aerogels (ASPN) points to a 54.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recent Price Trend in Aspen Aerogels (ASPN) is Your Friend, Here's Why
by Zacks Equity Research
Aspen Aerogels (ASPN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks.com featured highlights Freshpet, American Public Education, Aspen Aerogels, Cerence and Pinterest
by Zacks Equity Research
Freshpet, American Public Education, Aspen Aerogels, Cerence and Pinterest have been highlighted in this Screen of The Week article.
5 Stocks to Buy for Remarkable Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Freshpet (FRPT), American Public Education (APEI), Aspen Aerogels (ASPN), Cerence (CRNC) and Pinterest (PINS) for superb earnings acceleration.
Wall Street Analysts Believe Aspen Aerogels (ASPN) Could Rally 93.19%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 93.2% upside potential for Aspen Aerogels (ASPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Aspen Aerogels (ASPN) Have the Potential to Rally 108.33% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 108.3% upside potential for Aspen Aerogels (ASPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Should You Buy Aspen Aerogels (ASPN) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Wall Street Analysts Predict a 178.5% Upside in Aspen Aerogels (ASPN): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 178.5% upside potential for Aspen Aerogels (ASPN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bears are Losing Control Over Aspen Aerogels (ASPN), Here's Why It's a 'Buy' Now
by Zacks Equity Research
Aspen Aerogels (ASPN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Aspen Aerogels (ASPN) Soars 26.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Aspen Aerogels (ASPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
What's in the Cards for Sherwin-Williams (SHW) in Q3 Earnings?
by Zacks Equity Research
Sherwin-Williams (SHW) is expected to have benefited from strong demand in its domestic markets, cost-saving from restructuring initiatives and pricing actions in Q3.
Otis Worldwide (OTIS) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Otis Worldwide (OTIS) third-quarter 2023 results are likely to benefit from higher volume, favorable pricing and productivity.
Aspen Aerogels (ASPN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Aspen Aerogels (ASPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Much Upside is Left in Aspen Aerogels (ASPN)? Wall Street Analysts Think 190.93%
by Zacks Equity Research
The mean of analysts' price targets for Aspen Aerogels (ASPN) points to a 190.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Aspen Aerogels (ASPN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of 38.89% and 1.87%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aspen Aerogels (ASPN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspen Aerogels (ASPN) delivered earnings and revenue surprises of 41.46% and 6.72%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?